Tabcorp (ASX:TAH) reports their statutory NPAT for the 12 months ending June 30th increased to $365.5 million from $28.7 million from the prior corresponding period.
Revenue is up 45.9 per cent on the prior corresponding period to $5.48 billion.
EBITDA is up 38.4 per cent to $1 billion.
Shares in Tabcorp (ASX:TAH) are trading 1.49 per cent lower at $4.30.
Copyright 2019 – Finance News Network
Source: Finance News Network
12 Dec 2019 - Toll road operator, Atlas Arteria (ASX:ALX) has successfully completed its A$1.35 billion equity raising including the fully underwritten 4 for 21 pro-rata accelerated non-renounceable entitlement offer.
Read More07 Jul 2020 - Afterpay’s (ASX:APT) trading update for the three month period ended 30 June 2020 shows strong performance delivering underlying sales of $11.1 billion in FY20, more than doubling the prior corresponding period, up 112 per cent.
Read More18 Mar 2021 - CIMIC Group (ASX:CIM) company, CPB Contractors has been selected by the Queensland Government to deliver the Bruce Highway upgrade.
Read More09 Oct 2024 - A snapshot of the stocks on the move, featuring NOVONIX (NASDAQ:NVX, ASX:NVX), Patagonia Lithium (ASX:PL3) and Riversgold (ASX:RGL).
Read More21 Feb 2020 - Pilbara Minerals (ASX:PLS) saw weaker customer demand and lower spodumene concentrate prices which both impacted the company’s half year results.
Read More23 Apr 2020 - REA Group (ASX:REA) Company Secretary, Sarah Turner to leave.
Read More14 Apr 2021 - Brainchip (ASX:BRN)’s announcement of the commencement of microprocessor volume production has catapulted shares in the artificial intelligence (AI) innovator.
Read More17 Jan 2024 - A snapshot of the stocks on the move, featuring Intra Energy Corporation (ASX:IEC), Pinnacle Minerals (ASX:PIM) and Minerals 260 (ASX:MI6).
Read More28 Nov 2019 - Further to the announcement made on 5 November 2019 that an in-principle settlement of the securities class action against Bellamy’s Australia (ASX:BAL) had been reached, IMF Bentham (ASX:IMF) says it has progressed to an executed binding settlement agreement.
Read More25 Jun 2020 - CSL (ASX:CSL) has agreed to acquire from uniQure exclusive global license rights to commercialise an adeno-associated virus gene therapy program, for the treatment of haemophilia B.
Read More
